DAX 40 Rises Led by Infineon

The DAX Index went up by 165 points or 0.66 percent on Tuesday to close at 25011 points. The rise was led by Infineon (5.84%), Siemens Energy (3.60%) and Fresenius Medical Care (2.39%). On the downside, the weakerst performers were Munich RE (-3.17%), Hannover Rueck (-2.92%) and Siemens Healthineers (-2.07%).

Frankfurt’s DAX 40 rose to above 25,000 on Tuesday, supported by a rebound in global technology stocks as investors positioned for major earnings releases. The US tech sector led the recovery, with the Nasdaq 100 up more than 1% as companies linked to artificial intelligence continued to attract demand. Semiconductor maker Infineon jumped 5.8%, benefiting from renewed interest in chip stocks following stronger export data from South Korea and Taiwan. Siemens Energy also advanced nearly 4% as investors focused on its role in supplying power infrastructure for expanding data centres. Industrials were among the strongest performers, with Siemens gaining almost 2% and Airbus rising 1.3%. Banks also moved higher, while healthcare stocks received a boost after Swiss pharmaceutical group Novartis reported better-than-expected second quarter sales and earnings.

Frankfurt's DAX 40 hovered near the flatline around 24,840 on Tuesday as investors remained cautious amid ongoing uncertainty in the Middle East. While reports suggest mediators are working toward a renewed ceasefire between the US and Iran, US military strikes have continued for a tenth consecutive night. Elevated oil prices have reinforced expectations that the ECB will deliver about two additional rate hikes by December, with the first now fully priced in for September. At this week's ECB meeting, policymakers are widely expected to leave interest rates unchanged as they assess the impact of June's hike. Among stocks, Jungheinrich fell over 4% after Germany's financial watchdog, BaFin, opened an accounting investigation into its first-half 2025 financial statements. Zalando slipped more than 1% after BaFin flagged a disclosure error in its 2025 annual report, though no fine was imposed. Redcare Pharmacy rose 3.6% after Warburg Research highlighted its long-term margin potential.